

# Joaquin Mateo

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/160769/joaquin-mateo-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

84  
papers

8,876  
citations

36  
h-index

94  
g-index

96  
ext. papers

12,008  
ext. citations

11.7  
avg, IF

5.47  
L-index

#	Paper	IF	Citations
84	Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.. <i>Cancer Research</i> , <b>2022</b> , 82, 1646-1657	10.1	4
83	Delivering precision oncology to patients with cancer.. <i>Nature Medicine</i> , <b>2022</b> , 28, 658-665	50.5	7
82	Clinical implications of homologous recombination repair mutations in prostate cancer. <i>Prostate</i> , <b>2022</b> , 82,	4.2	1
81	Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss of Heterozygosity Score. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	9
80	Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2021</b> , 81, 37-37	10.2	3
79	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. <i>Radiology</i> , <b>2021</b> , 299, 109-119	20.5	14
78	Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. <i>European Urology</i> , <b>2021</b> , 79, 519-529	10.2	8
77	Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. <i>European Journal of Cancer</i> , <b>2021</b> , 147, 74-83	7.5	5
76	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. <i>Cancer Discovery</i> , <b>2021</b> , 11, 2812-2827	24.4	15
75	Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
74	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , <b>2021</b> , 79, 736-746	10.2	0
73	Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. <i>European Urology</i> , <b>2021</b> , 79, 762-771	10.2	13
72	Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. <i>European Urology</i> , <b>2021</b> , 79, 200-211	10.2	24
71	Characterizing CDK12-Mutated Prostate Cancers. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 566-574	12.9	17
70	Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. <i>Journal of Pathology: Clinical Research</i> , <b>2021</b> , 7, 311-325	5.3	6
69	Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. <i>European Urology</i> , <b>2021</b> , 80, 243-253	10.2	3
68	The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 86, 102000	14.4	8

67	First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4777-4784	12.9	10
66	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 2091-2102	59.2	550
65	Genomics of lethal prostate cancer at diagnosis and castration resistance. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 1743-1751	15.9	85
64	Next-generation sequencing (NGS) of tumor tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC): The PROfound phase III study experience.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 195-195	2.2	5
63	Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , <b>2020</b> , 21, 162-174	21.7	244
62	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , <b>2020</b> , 1, 1041-1053	15.4	18
61	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 2345-2357	59.2	143
60	A decade of clinical development of PARP inhibitors in perspective. <i>Annals of Oncology</i> , <b>2019</b> , 30, 1437-1443	14.3	218
59	Genomic correlates of clinical outcome in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 11428-11436	11.5	383
58	Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2019</b> , 76, 676-685	10.2	41
57	Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer. <i>Current Oncology Reports</i> , <b>2019</b> , 21, 42	6.3	13
56	BRCA2 and Other DDR Genes in Prostate Cancer. <i>Cancers</i> , <b>2019</b> , 11,	6.6	43
55	Managing Nonmetastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2019</b> , 75, 285-293	10.2	83
54	Germline and Somatic Defects in DNA Repair Pathways in Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , <b>2019</b> , 1210, 279-300	3.6	4
53	Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. <i>European Urology</i> , <b>2019</b> , 75, 184-192	10.2	49
52	RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 687-697	12.9	26
51	Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. <i>European Urology</i> , <b>2018</b> , 73, 687-693	10.2	70
50	Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. <i>European Urology Focus</i> , <b>2018</b> , 4, 235-244	5.1	12

49	Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation With Bone Biopsy Histological and Molecular Features. <i>Investigative Radiology</i> , <b>2018</b> , 53, 96-102	10.1	24
48	SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5585-5593	12.9	74
47	Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1554-1560	10.3	42
46	A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). <i>Annals of Oncology</i> , <b>2018</b> , 29, 1895-1902	10.3	181
45	Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers. <i>European Urology Oncology</i> , <b>2018</b> , 1, 71-77	6.7	14
44	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 4441-4453	15.9	84
43	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 280-284	3.8	22
42	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. <i>Cancer Discovery</i> , <b>2017</b> , 7, 1006-1017	24.4	232
41	Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e801-e807	3.3	15
40	Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6070-6077	12.9	22
39	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5981-5992	12.9	73
38	Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. <i>Annals of Oncology</i> , <b>2017</b> , 28, 90-95	10.3	19
37	Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , <b>2017</b> , 120, E30-E44	5.6	47
36	DNA Repair in Prostate Cancer: Biology and Clinical Implications. <i>European Urology</i> , <b>2017</b> , 71, 417-425	10.2	132
35	Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. <i>Radiology</i> , <b>2017</b> , 283, 168-177	20.5	57
34	PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS5091-TPS5091	2.2	8
33	A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 in patients with mCRPC.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 135-135	2.2	3
32	High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. <i>Oncotarget</i> , <b>2017</b> , 8, 104430-104443	3.3	3

31	Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5071-5071	2.2	
30	A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 889-96	8.7	32
29	Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. <i>European Urology</i> , <b>2016</b> , 70, 985-992	10.2	92
28	Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2016</b> , 70, 724-731	10.2	47
27	Interrogating the Cancer Genome to Deliver More Precise Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2016</b> , 35, e577-83	7.1	1
26	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 443-53	59.2	791
25	Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2016</b> , 22, 353-356	2.2	19
24	Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. <i>Radiology</i> , <b>2016</b> , 280, 151-60	20.5	36
23	Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 485-493	3.3	21
22	An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib. <i>Targeted Oncology</i> , <b>2016</b> , 11, 401-15	5	81
21	Biomarkers for Metastatic Castration-resistant Prostate Cancer (mCRPC): Yes or No? Predictive and Response Biomarkers Towards Precision Medicine in mCRPC. <i>European Urology Focus</i> , <b>2016</b> , 2, 465-466	5.1	1
20	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4586-96	12.9	154
19	Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. <i>Annals of Oncology</i> , <b>2015</b> , 26, 750-755	10.3	139
18	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1697-708	59.2	1345
17	A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2015</b> , 4, 277-85	4.5	20
16	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , <b>2015</b> , 161, 1215-1228	56.2	1765
15	Sequencing of agents in castration-resistant prostate cancer. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, e279-92	21.7	123
14	Switching and withdrawing hormonal agents for castration-resistant prostate cancer. <i>Nature Reviews Urology</i> , <b>2015</b> , 12, 37-47	5.5	49

13	PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. <i>European Urology</i> , <b>2015</b> , 67, 795-802	10.2	143
12	Early CTC decline as a biomarker of response to treatment in castration-resistant prostate cancer (CRPC): Analysis of the COU-AA-301 and IMMC38 trials.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5014-5014 <sup>2-2</sup>		5
11	The promise of circulating tumor cell analysis in cancer management. <i>Genome Biology</i> , <b>2014</b> , 15, 448	18.3	38
10	Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. <i>British Journal of Cancer</i> , <b>2014</b> , 111, 2248-53	8.7	45
9	Molecular characterization and clinical utility of circulating tumor cells in the treatment of prostate cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2014</b> , e197-203	7.1	14
8	A first-in-human study of the anti- $\alpha_5\beta_1$ integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2014</b> , 74, 1039-46	3.5	27
7	Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. <i>British Journal of Cancer</i> , <b>2014</b> , 111, 828-36	8.7	33
6	External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone. <i>European Urology</i> , <b>2014</b> , 66, 8-11	10.2	19
5	Novel drugs targeting the androgen receptor pathway in prostate cancer. <i>Cancer and Metastasis Reviews</i> , <b>2014</b> , 33, 567-79	9.6	24
4	PARP Inhibitors. <i>Current Clinical Urology</i> , <b>2014</b> , 253-264		
3	Appraising iniparib, the PARP inhibitor that never was--what must we learn?. <i>Nature Reviews Clinical Oncology</i> , <b>2013</b> , 10, 688-96	19.4	66
2	Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. <i>Journal of Pathology</i> , <b>2013</b> , 229, 422-9	9.4	235
1	Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. <i>Molecular Diagnosis and Therapy</i> , <b>2012</b> , 16, 151-61	4.5	5